MesoCancerVac by Amphera for Metastatic Pancreatic Cancer: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MesoCancerVac overview
MesoCancerVac is under development for the treatment of pancreatic adenocarcinoma, malignant pleural mesothelioma, metastasized pancreatic ductal adenocarcinoma and peritoneal mesothelioma. It is administered through intravenous and intradermal routes. The therapy uses the autologous dendritic cells pulsed with allogeneic tumour cell lysates (fragments of tumor cells). Dendritic cells (DCs) possess the ability to stimulate antigen specific T cell.
Amphera overview
Amphera B.V., is a biotechnology company that focused on developing an immunotherapy for mesothelioma. The company is headquartered in The Netherlands.
For a complete picture of MesoCancerVac’s drug-specific PTSR and LoA scores, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#MesoCancerVac #Amphera #Metastatic #Pancreatic #Cancer #Likelihood #Approval
